GaBI news digest for 14 October 2022

Home/Pharma News | Posted 14/10/2022 post-comment0 Post your comment

Selected news for the week of 14 October 2022 for GaBI readers.

56 AA011042

WHO-South Korea biomanufacturing training hub initiative
Moving forward on goal to boost local pharmaceutical production, World Health Organization (WHO) establishes global biomanufacturing training hub in Republic of Korea

Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub.

Learn more ...

Drug shortages and unavailability of medicines
Improving the availability of medicines authorised in the European Union (EU) is a key priority for the European Medicines Agency (EMA) and the European medicines regulatory network. Shortages or other problems with the availability of medicines create challenges for the medicine supply chain, with a potentially serious impact on human and animal health.

Learn more ...

How generics competition helps bring down drug prices
Access to affordable medicines remains a significant public health priority for FDA. The agency regularly conducts economic analyses to measure the impact additional approved generic equivalents can have on consumer generic drug prices. The study below has continually demonstrated that greater competition from generic drugs can help lower drug prices and improve access to drugs for American patients and consumers.

Estimating Cost Savings from New Generic Drug Approvals In 2018, 2019, and 2020

Related articles
WHO revised guidelines for biosimilars: scientific background

Canada calls for support to national pharmacare and generics industry

UK NHS faces drug shortages

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010